ProQR Therapeutics (NASDAQ:PRQR) Issues Quarterly Earnings Results

ProQR Therapeutics (NASDAQ:PRQR) released its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.10), Zacks reports. ProQR Therapeutics had a negative return on equity of 71.58% and a negative net margin of 134.31%.

ProQR Therapeutics Price Performance

Shares of PRQR stock opened at $1.83 on Thursday. The stock’s 50-day moving average is $2.29 and its 200 day moving average is $2.62. ProQR Therapeutics has a 1-year low of $1.61 and a 1-year high of $4.62. The company has a market cap of $149.07 million, a P/E ratio of -5.66 and a beta of 0.24.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. Oppenheimer started coverage on ProQR Therapeutics in a report on Friday, January 10th. They issued an “outperform” rating and a $15.00 target price for the company. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of ProQR Therapeutics in a research report on Thursday, December 12th. JMP Securities restated a “market outperform” rating and issued a $8.00 target price on shares of ProQR Therapeutics in a report on Thursday, December 12th. Citigroup raised shares of ProQR Therapeutics from a “neutral” rating to a “buy” rating and set a $4.00 price target for the company in a research note on Monday. Finally, Chardan Capital restated a “buy” rating and set a $4.00 target price on shares of ProQR Therapeutics in a research report on Thursday, December 12th. One investment analyst has rated the stock with a sell rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $9.17.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).